Literature DB >> 19330025

Deleting Ku70 is milder than deleting Ku80 in p53-mutant mice and cells.

H Li1, Y J Choi, M A Hanes, T Marple, H Vogel, P Hasty.   

Abstract

Ku70 forms a heterodimer with Ku80, called Ku that is well known for repairing DNA double-strand breaks through non-homologous end joining. As a result, deletion of either causes a very similar phenotype in mice that includes hypersensitivity to clastogens and early aging. In addition, deletion of Ku80 along with the cell cycle checkpoint protein, p53, dramatically increases the incidence of pro-B-cell lymphoma. Even though Ku70- p53-mutant mice have not been analysed, a logical assumption is they would exhibit the same cancer phenotype. Here, we test this assumption by comparing p53-mutant littermates deleted for either Ku70 or Ku80 or both. We find this assumption to be incorrect as p53-mutants live significantly longer when deleted for Ku70 rather than Ku80 or Ku70+Ku80. We also find the former cohort displays much lower levels of pro-B-cell lymphoma than the latter two cohorts. As pro-B-cell lymphoma is caused by a translocation between chromosomes 12 and 15, we tested fibroblasts for DNA repair capacity, and found that p53-mutant fibroblasts are more sensitive to streptonigrin and paraquat when deleted for Ku80 as compared with Ku70. Thus, Ku80 may function outside the Ku heterodimer to influence DNA damage repair presenting the possibility that Ku80 influenced the open coding ends in a manner that suppressed a cancer-causing translocation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19330025     DOI: 10.1038/onc.2009.57

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  8 in total

1.  Ku is a 5'-dRP/AP lyase that excises nucleotide damage near broken ends.

Authors:  Steven A Roberts; Natasha Strande; Martin D Burkhalter; Christina Strom; Jody M Havener; Paul Hasty; Dale A Ramsden
Journal:  Nature       Date:  2010-04-11       Impact factor: 49.962

2.  Ku80-deleted cells are defective at base excision repair.

Authors:  Han Li; Teresa Marple; Paul Hasty
Journal:  Mutat Res       Date:  2013-04-06       Impact factor: 2.433

3.  Synthetic lethality between murine DNA repair factors XLF and DNA-PKcs is rescued by inactivation of Ku70.

Authors:  Mengtan Xing; Magnar Bjørås; Jeremy A Daniel; Frederick W Alt; Valentyn Oksenych
Journal:  DNA Repair (Amst)       Date:  2017-07-26

4.  Bax deficiency extends the survival of Ku70 knockout mice that develop lung and heart diseases.

Authors:  J Ngo; M Matsuyama; C Kim; I Poventud-Fuentes; A Bates; S L Siedlak; H-G Lee; Y Q Doughman; M Watanabe; A Liner; B Hoit; N Voelkel; S Gerson; P Hasty; S Matsuyama
Journal:  Cell Death Dis       Date:  2015-03-26       Impact factor: 8.469

5.  Chromosomal Rearrangements in Cancer: Detection and potential causal mechanisms.

Authors:  Paul Hasty; Cristina Montagna
Journal:  Mol Cell Oncol       Date:  2014-07

6.  Characterization of HIV-1 integrase interaction with human Ku70 protein and initial implications for drug targeting.

Authors:  Andrey N Anisenko; Ekaterina S Knyazhanskaya; Artur O Zalevsky; Julia Yu Agapkina; Aleksander I Sizov; Timofey S Zatsepin; Marina B Gottikh
Journal:  Sci Rep       Date:  2017-07-17       Impact factor: 4.379

7.  Deletion of individual Ku subunits in mice causes an NHEJ-independent phenotype potentially by altering apurinic/apyrimidinic site repair.

Authors:  Yong Jun Choi; Han Li; Mi Young Son; Xiao-Hong Wang; Jamie L Fornsaglio; Robert W Sobol; Moonsook Lee; Jan Vijg; Sandra Imholz; Martijn E T Dollé; Harry van Steeg; Erwin Reiling; Paul Hasty
Journal:  PLoS One       Date:  2014-01-23       Impact factor: 3.240

8.  The progeroid phenotype of Ku80 deficiency is dominant over DNA-PKCS deficiency.

Authors:  Erwin Reiling; Martijn E T Dollé; Sameh A Youssef; Moonsook Lee; Bhawani Nagarajah; Marianne Roodbergen; Piet de With; Alain de Bruin; Jan H Hoeijmakers; Jan Vijg; Harry van Steeg; Paul Hasty
Journal:  PLoS One       Date:  2014-04-16       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.